241 related articles for article (PubMed ID: 17374827)
1. For organ transplant recipients, cancer threatens long-term survival.
Ross K
J Natl Cancer Inst; 2007 Mar; 99(6):421-2. PubMed ID: 17374827
[No Abstract] [Full Text] [Related]
2. Transplantation and tumors.
Morales JM
Nefrologia; 2006; 26 Suppl 2():12-20. PubMed ID: 17937631
[No Abstract] [Full Text] [Related]
3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
4. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
[TBL] [Abstract][Full Text] [Related]
5. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive drugs and the risk of cancer after organ transplantation.
Dantal J; Soulillou JP
N Engl J Med; 2005 Mar; 352(13):1371-3. PubMed ID: 15800234
[No Abstract] [Full Text] [Related]
8. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of a child having generalized Kaposi's sarcoma after living donor liver transplantation with conversion to sirolimus.
Yuksekkaya HA; Arikan C; Yazici A; Baran M; Aydogdu S; Kilic M
Pediatr Transplant; 2009 May; 13(3):375-8. PubMed ID: 18452496
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus, the first mTOR inhibitor.
Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
[No Abstract] [Full Text] [Related]
11. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant.
Teachey DT; Jubelirer T; Baluarte HJ; Wade A; Manno CS
Pediatr Blood Cancer; 2009 Dec; 53(6):1114-6. PubMed ID: 19621445
[TBL] [Abstract][Full Text] [Related]
12. [Pro- and antitumor effects of the main immunosuppressive drugs used in the clinical practice of transplantation].
Marchini F
G Ital Nefrol; 2007; 24(2):171. PubMed ID: 17458835
[No Abstract] [Full Text] [Related]
13. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
Cruzado JM
Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
[TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
15. Cardiac transplantation without calcineurin inhibitors. Sirolimus as first immunosuppressive line. Based on one case.
Lage E; Cabezón S; Hinojosa R; Ordóñez A; Campos A
Transpl Int; 2006 Jan; 19(1):84. PubMed ID: 16359382
[No Abstract] [Full Text] [Related]
16. [Cancer in organ transplanted patients].
Pfeffer PF
Tidsskr Nor Laegeforen; 1999 Oct; 119(25):3792-4. PubMed ID: 10574060
[TBL] [Abstract][Full Text] [Related]
17. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.
Barau C; Blouin P; Creput C; Taburet AM; Durrbach A; Furlan V
Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitors and rapamycin: cancer protection or promotion?
Weischer M; Röcken M; Berneburg M
Exp Dermatol; 2007 May; 16(5):385-93. PubMed ID: 17437481
[TBL] [Abstract][Full Text] [Related]
19. [The risk of malignancy after organ transplantation].
Gürlich R; Novotný J; Stríz I; Honsová E; Oliverius M; Janousek L; Pokorná E; Maruna P
Cas Lek Cesk; 2005; 144(9):597-600; discussion 600-1. PubMed ID: 16193937
[TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
